3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
14
Neoplasm Metastasis
7
Recurrence
3
Neoplasms
2
Melanoma
2
Uveal Melanoma
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein
1
Squamous Cell Carcinoma of Head and Neck
1
Rectal Neoplasms
1
Pre-menopausal Breast Cancer
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Multiple Myeloma
1
Meningioma
1
Kidney Neoplasms
1
Head and Neck Squamous Cell Cancer
1
Head and Neck Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Ductal, Breast
1
Advanced or Metastatic ER+ Breast Cancer
1
Advanced and Selected Solid Tumors
1
Advanced Solid Tumors With an Alteration of the PIK3CA Gene
1
Advanced Solid Tumor
1
Acrocephalosyndactylia
1
3rd Line GIST
1
Interventions
NVP-BKM120
1
Alpelisib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Pre-menopausal Breast Cancer
×
Alpelisib
×
Clear all
NCT02058381
2020-03-09
B-YOND
Novartis
Phase 1
Completed
40 enrolled